LY-3200882

DB16064InvestigationalSmall molecule

LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).

Chemical structure of LY-3200882
Formula / weight
C24H29N5O3 · 435.528 g/mol (avg)
Code names
LY-3200882

Resolves to

Compound
UNII19HY34R6UNCAS1898283-02-7
Structure
InChIKeyPNPFMWIDAKQFPY-UHFFFAOYSA-NSMILESCC(C)(O)C1=CC(NC2=CC(OC3=CN(N=C3C3CCOCC3)C3CC3)=CC=N2)=CC=N1
Targets
P36897TGFBR1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with LY-3200882, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In